Cancer Commissioning—at a global and a local level: London Cancer New Drugs Group Annual Meeting

Conference Coverage

Introduction

Additional private care in practice

Patient-access schemes in cancer care

End-of-life care—the anomalies

Very rare cancers—the challenge

Funding UK cancer services—are there realistic alternatives?

Pan-London approach to prioritising new cancer drugs

Discussion points

Conclusions

Page 1 of 16

Next Page

---